CAS: 37784-17-1; Boc-D-Pro-Oh

相似化合物

59433-50-0 13200-83-4 68078-09-1

上下游产品

CAS号24424-99-5 二碳酸二叔丁酯 | CAS号344-25-2 D-脯氨酸 | CAS号124-38-9 二氧化碳 | CAS号86953-79-9 1-B°C-四氢吡咯 | CAS号58632-95-4 2-(叔-丁氧基碳酰胺)-2-苯乙腈 | CAS号350022-46-7 N-(tert-butoxyc... | CAS号73286-71-2 N-B°C-2-吡咯啉 | CAS号73365-02-3 B°C-D-脯氨醛 | CAS号105959-87-3 tert-butyl (2R)... | CAS号550378-07-9 R-叔丁氧羰基-2-(氨基甲基)吡咯烷 | CAS号35150-07-3 B°C-L-脯氨酸酰胺 | CAS号60419-23-0 (R)-(-)-1-(2-吡咯... | CAS号68295-45-4 (R)-(-)-2-(苯氨基甲基)吡咯烷 | CAS号69610-40-8 B°C-L-脯氨醇 | CAS号73365-02-3 B°C-D-脯氨醛 | CAS号73323-65-6 B°C-D-脯氨酸甲酯 | CAS号70138-72-6 N-B°C-D-脯氨酰胺 | CAS号128510-88-3 (R)-2-(甲苯磺酰氧基甲基...

专利信息

专利号:US-2022356182-A1
优先权日:2009-03-27
标题 :Inhibitors of hepatitis c virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOLL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-11053243-B2
优先权日:2009-03-27
标 题:Inhibitors of hepatitis C virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOIL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-9090661-B2
优先权日:2009-03-27
标 题:Inhibitors of hepatitis C virus replication
发明人：COBURN CRAIG A; MCCAULEY JOHN A; LUDMERER STEVEN W; LIU KUN; VACCA JOSEPH P; WU HAO; HU BIN; SOLL RICHARD; SUN FEI; WANG XINGHAI; YAN MAN; ZHANG CHENGREN; ZHENG MINGWEI; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-7402670-B2
优先权日:2004-09-30
标 题:Synthesis by chiral diamine-mediated asymmetric alkylation
发明人：DENG XIAOHU; MANI NEELAKANDHA
权利人:JANSSEN PHARMACEUTICA NV
摘要:Chiral synthesis from an achiral starting material by chiral diamine-mediated, such as sparteine-mediated, intermolecular asymmetric alkylation with a strained cyclic ether in the presence of a Lewis acid.

专利号:US-5633346-A
优先权日:1992-06-19
标 题:Process for systhesizing cyclic peptides
发明人：KUROME TORU; TAKESAKO KAZUTOH; KATO IKUNOSHIN; INAMI KAORU; SHIBA TETSUO
权利人:TAKARA SHUZO CO
摘要:A process is provided for the total synthesis of a cyclic peptide, which is useful as antifungal drug, and novel compounds prepared by the synthesis method. The cyclic peptide is represented by the following formula (I): (I) wherein X1, X2, X4 and X7 are independently N-methyl- alpha -amino acid or alpha -hydroxy acid, provided that at least one of X1, X2, X4 and X7 is an alpha -hydroxy acid; X3, X6 and X8 are independently alpha -amino acid; X5 is a cyclic amino acid; X9 is an N-methyl- alpha -amino acid or alpha -hydroxy acid substituted by a hydroxy group; and the dotted lines represent intramolecular hydrogen bonds. The process includes cyclizing a corresponding linear peptide between X5 and X6 via a peptide bond.